| [1] |
Carson R T. Patient experience data for medical product development: opportunity beyond obligation[J]. Patient, 2022, 15(2): 147-149. DOI: 10.1007/s40271-021-00570-8.
|
| [2] |
Donabedian A. The Lichfield Lecture. Quality assurance in health care: consumers' role[J]. Qual Health Care, 1992, 1(4): 247-251. DOI: 10.1136/qshc.1.4.247.
|
| [3] |
Auras S, Geraedts M. Patient experience data in practice accreditation—an international comparison[J]. Int J Qual Health Care, 2010, 22(2): 132-139. DOI: 10.1093/intqhc/mzq006.
|
| [4] |
Congress of the United States. H.R. 34-21st Century Cures Act [A/OL]. (2016-12-13)[2024-09-01].
|
| [5] |
国家药品监督管理局药品审评中心. 关于发布《以患者为中心的药物临床试验设计技术指导原则(试行)》《以患者为中心的药物临床试验实施技术指导原则(试行)》《以患者为中心的药物获益-风险评估技术指导原则(试行)》的通告: 2023年第44号[A/OL].(2023-07-27)[2024-09-01].
|
| [6] |
Food and Drug Administration. eCTD technical conformance guide [EB/OL]. [2024-09-01].
|
| [7] |
Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input[EB/OL]. [2024-09-01].
|
| [8] |
Bertelsen N, Dewulf L, Ferrè S, et al. Patient engagement and patient experience data in regulatory review and health technology assessment: a global landscape review[J]. Ther Innov Regul Sci, 2024, 58(1): 63-78. DOI: 10.1007/s43441-023-00573-7.
|
| [9] |
Liu I T T, Kesselheim A S. Drug repurposing via the best pharmaceuticals for children act[J]. JAMA Pediatr, 2024, 178(9): 855-856. DOI: 10.1001/jamapediatrics.2024.2287.
|
| [10] |
Food and Drug Administration. Challenge and opportunity on the critical path to new medical products[R]. Washington: FDA, 2004.
|
| [11] |
Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims [EB/OL]. [2024-09-01].
|
| [12] |
U.S. Government Information. Patient protection and affordable care act[EB/OL]. (2010-03-23)[2024-09-01].
|
| [13] |
Food and Drug Administration Food and Drug Administration safety and innovation act[EB/OL].(2020-11-04)[2024-09-01].
|
| [14] |
United States Congress. Prescription Drug User Fee ActⅤ[EB/OL].(2012-07-09)[2024-09-01].
|
| [15] |
Mullin T. Fda Working with patients to explore benefit/risk: opportunities & challenges: patient-focused drug development [EB/OL].(2012-05-18)[2024-09-01].
|
| [16] |
Mullin T. Patient focused drug development: power point presentation[EB/OL]. (2012-05-18)[2024-09-01].
|
| [17] |
Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients [EB/OL]. [2024-09-01].
|
| [18] |
Food and Drug Administration. Patient-focused drug development: selecting, developing or modifying fit-for-purpose clinical outcomes assessments[EB/OL]. [2024-09-01].
|
| [19] |
Food and Drug Administration. Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making [EB/OL]. [2024-09-01].
|
| [20] |
国家药品监督管理局药品审评中心. 关于发布《患者报告结局在药物临床研发中应用的指导原则(试行)》的通告2021年第62号[EB/OL]. (2021-12-27)[2024-09-01].
|
| [21] |
国家药品监督管理局药品审评中心. 关于发布《组织患者参与药物研发的一般考虑指导原则(试行)》的通告: 2022年第46号[EB/OL]. (2022-11-21)[2024-09-01].
|
| [22] |
国家药品监督管理局药品审评中心. 关于公开征求《以患者为中心的罕见疾病药物研发试点工作计划("关爱计划")》申报指南和实施框架意见的通知 [EB/OL]. (2024-05-24)[2024-09-01].
|
| [23] |
国家药品监督管理局药品审评中心. 关于公开征求《以患者为中心的中药新药临床研发技术指导原则(征求意见稿)》意见的通知 [EB/OL]. (2024-11-19)[2024-12-08].
|
| [24] |
Haerry D, Landgraf C, WarneR K, et al. EUPATI and patients in medicines research and development: guidance for patient involvement in regulatory processes [J]. Front Med(Lausanne), 2018, 5: 230. DOI: 10.3389/fmed.2018.00230.
|
| [25] |
European Medicines Agency. Multi-stakeholder workshop: patient experience data in medicines development and regulatory decision-making[EB/OL]. (2022-09-21)[2024-09-01].
|
| [26] |
European Medicines Agency. Update on patient experience data(PED)[EB/OL]. (2023-11-24)[2024-09-01].
|
| [27] |
European Medicines Agency. Patient experience data in EU medicines development and regulatory decision-making[EB/OL].(2022-09-21)[2024-09-01].
|
| [28] |
|
| [29] |
Karagiannis T, Avgerinos I, Toumpalidou M, et al. Patients' and clinicians' preferences on outcomes and medication attributes for type 2 diabetes: a mixed-methods study[J]. J Gen Intern Med, 2020. DOI: 10.1007/s11606-019-05608-0.
|
| [30] |
Staunton H, Kelly K, Newton L, et al. A patient-centered conceptual model of symptoms and their impact in early Parkinson's disease: a qualitative study[J]. J Parkinsons Dis, 2022, 12(1): 137-151. DOI: 10.3233/JPD-202457.
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
Connelly K, Eades L E, Koelmeyer R, et al. Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce[J]. Nat Rev Rheumatol, 2023, 19(9): 592-602. DOI: 10.1038/s41584-023-00993-7.
|
| [35] |
|
| [36] |
Katz E G, Mcnulty P, Levitan B, et al. U.S. Food and Drug Administration's patient-focused drug development initiative: experience with integration of patient-experience data in a new drug application for esketamine nasal spray plus a newly initiated oral antidepressant for treatment-resistant depression[J]. Ther Innov Regul Sci, 2022, 56(1): 38-46. DOI: 10.1007/s43441-021-00340-6.
|
| [37] |
Kieffer C M, Miller A R, Chacko B, et al. FDA reported use of patient experience data in 2018 drug approvals[J]. Ther Innov Regul Sci, 2020, 54(3): 709-716. DOI: 10.1007/s43441-019-00106-1.
|
| [38] |
Oehrlein E M, Schoch S, Burcu M, et al. Developing patient-centered real-world evidence: emerging methods recommendations from a consensus process[J]. Value Health, 2023, 26(1): 28-38. DOI: 10.1016/j.jval.2022.04.1738.
|
| [39] |
Oehrlein E M, Burcu M, Schoch S, et al. Enhancing patient centricity of real-world data research: an exploratory analysis using the patient experience mapping toolbox[J]. Value Health, 2023, 26(1): 10-17. DOI: 10.1016/j.jval.2022.10.002.
|
| [40] |
Wiig S, Rutz S, Boyd A, et al. What methods are used to promote patient and family involvement in healthcare regulation? A multiple case study across four countries[J]. BMC Health Serv Res, 2020, 20(1): 616. DOI: 10.1186/s12913-020-05471-4.
|
| [41] |
Lowell A, Jones Y, Aitken R, et al. Why surveys are 'very hard': exploring challenges and insights for collection of authentic patient experience information with speakers of Australian first nations languages[J]. Rural Remote Health, 2024, 24(2): 8380. DOI: 10.22605/RRH8380.
|
| [42] |
European Medicines Agency. Terms of reference for the European Medicines Agency / Food and Drug Administration cluster on patient engagement[EB/OL]. (2016-06-22)[2024-09-01].
|
| [43] |
Pinto C A, Tervonen T, Jimenez-Moreno C, et al. Current practices and challenges when submitting patient experience data for regulatory decisions by the US food and drug administration: an industry survey[J]. Patient Patient Centered Outcomes Res, 2024, 17(2): 147-159. DOI: 10.1007/s40271-023-00653-8.
|
| [44] |
Song H J, Dennis S, Levesque J F, et al. How to implement patient experience surveys and use their findings for service improvement: a qualitative expert consultation study in Australian general practice[J]. Integr Healthc J, 2020, 2(1): e000033. DOI: 10.1136/ihj-2019-000033.
|
| [45] |
Almeida D, Umuhire D, Gonzalez-Quevedo R, et al. Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU[J]. Front Med, 2024, 11: 1408636. DOI: 10.3389/fmed.2024.1408636.
|
| [46] |
Willgoss T, Escontrias O A, Scrafton C, et al. Co-creation of the global patient experience data navigator: a multi-stakeholder initiative to ensure the patient voice is represented in health decision-making[J]. Res Involv Engagem, 2023, 9(1): 92. DOI: 10.1186/s40900-023-00503-9.
|